Skip to main content

Table 2 Main outcomes for the primary, secondary, sensitivity and negative outcome analyses

From: Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care

 

Primary Analysis

Sensitivity Analysis

Primary Analysis

Sensitivity Analysis

ACE-I

CCB

ACE-I

+/− CCB

CCB

ARB

CCB

ARB

+/− CCB

CCB

Suspected or confirmed COVID-19

 Propensity score matched analysis

  Outcome events, n (%)

83 (0.44)

85 (0.45)

108 (0.45)

108 (0.45)

79 (0.74)

58 (0.55)

88 (0.66)

75 (0.57)

  Person-years

8923

8932

11,211

11,219

5010

5016

6258

6267

  Crude incidence rate/1000 person-years

9.30

9.52

9.63

9.63

15.77

11.56

14.06

11.97

  Unadjusted incidence rate ratio (95% CI)

0.98 (0.72–1.32) p = 0.885

1.00 (0.77–1.31) p = 0.994

1.36 (0.97–1.91) p = 0.072

1.18 (0.86–1.60) p = 0.304

  Adjusted hazard ratio (95% CI)

0.92 (0.68–1.26) p = 0.609

0.95 (0.72–1.24) p = 0.703

1.38 (0.98–1.95) p = 0.062

1.18 (0.86–1.61) p = 0.303

All-cause mortality

 Propensity score matched Analysis

  Outcome events, n (%)

102 (0.54)

66 (0.35)

131 (0.55)

109 (0.46)

40 (0.38)

50 (0.47)

55 (0.41)

70 (0.53)

  Person-years

8941

8950

11,234

11,242

5028

5028

6278

6282

  Crude incidence rate/1000 person years

11.41

7.37

11.66

9.70

7.96

9.94

8.76

11.14

  Unadjusted incidence rate ratio (95% CI)

1.55 (1.14–2.11) p = 0.006

1.20 (0.93–1.55) p = 0.155

0.80 (0.53–1.21) p = 0.293

0.79 (0.55–1.12) p = 0.182

  Adjusted hazard ratio (95% CI)

1.25 (0.90–1.73) p = 0.182

1.00 (0.77–1.30) p = 0.977

0.85 (0.56–1.30) p = 0.458

0.76 (0.53–1.09) p = 0.138

Negative Control Outcome (Trauma/Accidents/Injury)

 PS Matched Analysis

  Outcome events, n (%)

185 (0.98)

187 (0.99)

246 (1.04)

246 (1.04)

105 (0.99)

108 (1.02)

137 (1.03)

146 (1.10)

  Person-years

8898

8904

11,176

11,182

5004

5002

6245

6246

  Crude incidence rate/1000 person years

20.79

21.00

22.01

22.00

20.98

21.59

21.94

23.37

  Unadjusted incidence rate ratio (95% CI)

0.99 (0.81–1.21) p = 0.923

1.00 (0.84–1.19) p = 0.996

0.97 (0.74–1.27) p = 0.835

0.94 (0.74–1.18) p = 0.594

  Adjusted hazard ratio (95% CI)

0.95 (0.77–1.17) p = 0.640

0.96 (0.80–1.14) p = 0.620

0.97 (0.74–1.27) p = 0.801

0.91 (0.72–1.15) p = 0.439

  1. ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, CCB calcium channel blocker